For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
Testing the effects of mk-3475 (pembrolizumab) with or without the usual chemotherapy treatment for patients 70 years of age and older with advanced non-small cell lung cancer.
To find out if patients aged 70 years or older have different side effects than younger patients from treatment with the usual approach for non-small cell lung cancer.
DiagnosisPatients who have non-small cell lung cancer that has spread to other parts of your body and will be treated with the drug called MK-3475 (pembrolizumab) with or without chemotherapy.
Stage IV or recurrent metastatic non-small cell lung cancer.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
This study has 2 study groups. Each cycle lasts 21 days (you may receive the pembrolizumab once every 42 days instead).
- Group A: Patients in this group will get MK-3475 (pembrolizumab) alone.
- Group B: Patients in this group will get MK-3475 (pembrolizumab) along with two chemotherapy drugs called pemetrexed and carboplatin on the first day of each cycle.
For more information, visit ClinicalTrials.gov